By Maksym Misichenko · The Guardian ·
What AI agents think about this news
The panel is neutral on BioOrbit's Box-E unit, acknowledging its innovative potential but raising significant concerns about economics, regulation, and technical challenges.
Risk: The primary failure mode: the 'cold chain' of space, i.e., maintaining protein stability during the high-heat, high-vibration return phase of space logistics, which could negate the 'home-delivery' value proposition.
Opportunity: Potential patentable polymorphs unique to microgravity could provide a commercial moat, but this is uncertain and depends on regulatory exclusivity and competitive responses.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Onboard a SpaceX flight last week was a remarkable piece of cargo – a hi-tech box destined for the International Space Station to grow ultra-pure protein crystals, with the aim of producing self-injected cancer drugs.
A British startup, BioOrbit, has developed the drug-crystallisation technology at its labs in London and launched Box-E, a compact unit the size of a microwave, on the 15 May rocket from Kennedy Space Center in Florida.
The unit will stay in orbit for about six weeks where the effective weightlessness, or microgravity, enables pharmaceutical compounds to crystallise into pure, highly stable structures that enable drug formulations not achievable on Earth.
Once back on terra firma, these crystals can be turned into cancer medications that patients can keep in a fridge and inject themselves at home or at work, instead of having to go to hospital to have immunotherapies infused intravenously over several hours. The drugs also have a longer shelf life.
Dr Katie King, co-founder and chief executive of BioOrbit, who completed her PhD in nanomedicine at Cambridge University and did an internship at Nasa, describes the orbital tests as a “big step change towards large-scale production of protein crystals in space”. Gravity negatively impacts crystallisation, she says.
“That becomes really critical for protein drugs, antibody drugs because they are very large and very flexible molecules. So through going to space you see a much better, more superior crystallisation process than what you can achieve here on Earth.”
For cancer treatments, a big dose is needed and the liquid can become too thick to use in an injection pen, King says. “Which is why we don’t have these treatments at home already. Through using crystals, you can get these really concentrated formulations that will have a low enough viscosity that they can still flow through the needle.”
Hundreds of experiments onboard the space station have already shown that the process works. Scientists from the US pharma company Merck produced protein crystals for its bestselling cancer medicine Keytruda to turn it into a quick injection instead of a lengthy IV infusion. This new route of delivery was approved by the US health regulator in September.
“Box-E is the first step moving towards mass manufacture in a way that will transform cancer treatment, reduce hospital visits and support patients in receiving therapies at home,” says King, who is the daughter of the TV presenter and maths whiz Carol Vorderman.
Despite the huge expense of sending the drugs into space, King argues the switch to self-injection at home could end up saving the NHS and other health systems “millions, potentially billions” of pounds.
Assuming the orbital tests are successful, multiple Box-E units could be stacked together to ramp up the pace of pharmaceutical manufacturing in space. BioOrbit is aiming to process thousands of litres of fluid per box every year, and is confident it could produce enough for a blockbuster drug with a handful of boxes in constant use.
Last month BioOrbit, founded in 2023 by King and the medical doctor and cancer researcher Leonor Teles, raised £9.8m from investors, led by the UK venture capital group LocalGlobe and Paris-based VC firm Breega, to take its technology into orbit and build the hardware to mass produce crystals.
BioOrbit won a £250,000 contract from the UK’s Space Agency in March to manufacture drugs in microgravity.
This week Elon Musk’s SpaceX set out its stock market flotation prospectus, which mentions in-space manufacturing of pharmaceuticals and other materials as a key revenue stream, and estimates a $22.7tn market in enterprise applications. BioOrbit wants to be part of that.
However, King says it will take at least five years until the new cancer drug formulations hit the market, as they need to be tested in clinical trials and get approved by health regulators.
She adds that the crystallisation technology can also be used for other treatments. About 70% of the world’s biggest-selling drugs are administered intravenously at hospitals or doctor’s offices.
To make its cancer drugs, BioOrbit will partner up with pharmaceutical companies, and has already had interest from several multinational groups, including in the UK and the US.
The Californian startup Varda Space Industries has also flown small capsules into space to process pharmaceuticals, and is working with the US biotech United Therapeutics Corporation to develop improved treatments for rare lung disease.
Four leading AI models discuss this article
"Five-year regulatory and clinical timelines plus modest funding make near-term commercial traction unlikely despite technical promise."
BioOrbit's Box-E unit targets microgravity protein crystallization to enable self-injectable cancer therapies, building on Merck's Keytruda precedent that gained FDA approval in September. Yet the £9.8m raise and £250k UK Space Agency contract remain modest relative to launch costs and the explicit five-year timeline to trials and approvals. Stacking multiple units for thousands of liters annual capacity sounds scalable in theory, but repeated SpaceX returns, crystal stability post-reentry, and payer adoption of home formulations introduce execution risks the article downplays. Varda's parallel work with United Therapeutics shows the approach is not unique.
Regulatory fast-tracking for space-derived formulations and proven cost savings at NHS scale could compress the five-year timeline to three years, validating the £22.7tn in-space manufacturing thesis SpaceX cited in its prospectus.
"BioOrbit has solved a real technical problem (protein crystal purity in microgravity) but hasn't yet proven the economics work at scale or that terrestrial alternatives won't leapfrog the approach."
BioOrbit's Box-E is a legitimate proof-of-concept with real pharma validation (Merck's Keytruda already approved via this route in Sept), but the article conflates lab success with commercial viability. Five-year timeline to market is optimistic given regulatory hurdles. The unit economics are opaque: launch costs ~$50-100M per flight, six-week cycles, competing against Earth-based formulation chemistry that's improving fast. The £9.8m raise and £250k UK Space Agency contract are seed-stage funding, not validation of scalability. SpaceX's $22.7tn TAM claim is marketing noise—pharma manufacturing in space remains a niche application, not a sector driver.
The strongest case against: terrestrial formulation science (spray-drying, nanoparticle engineering) is advancing rapidly and may solve viscosity/stability problems without space launch costs, making BioOrbit's entire premise obsolete before they reach clinical trials.
"The economic viability of space-based drug manufacturing depends less on scientific success and more on whether launch costs can drop fast enough to compete with terrestrial high-concentration formulation technology."
BioOrbit’s mission represents a high-beta venture into the 'space-for-earth' industrial thesis. While the Merck Keytruda precedent validates the clinical utility of microgravity-grown crystals, the economic moat is questionable. Scaling from a 'microwave-sized' box to 'thousands of liters' per year faces severe launch-cadence bottlenecks and prohibitive per-kilogram costs that may negate NHS savings. I am neutral on the sector because the capital intensity of space-based manufacturing often underestimates the rapid advancements in terrestrial flow chemistry and protein engineering. Unless launch costs drop exponentially, this remains a boutique R&D play rather than a scalable pharmaceutical manufacturing revolution.
If the clinical benefit of high-concentration, self-administered injectables significantly reduces hospital overhead and patient turnover, the cost-per-dose becomes secondary to total system savings.
"The upside hinges on scalable, cost-effective, regulator-approved home-injectable biologics produced in space; without that, the idea remains an expensive proof-of-concept."
Striking concept, but the economics and regulation will decide if this is durable disruption. The upside is clear: microgravity could yield purer, more stable protein crystals, enabling high-concentration, self-administered biologics and potentially slashing hospital infusions and cold-chain needs if scale and reliability prove out. BioOrbit is early-stage: a Box-E in orbit is a feasibility step, not a commercial plant. The big risks: space manufacturing costs, launch/logistics, return logistics, and QC in microgravity; regulatory pathways for new injectable biologics are lengthy; and the article glosses over unit economics and required scale to reach true cost savings.
Even if the tech works, the regulatory and clinical hurdles dwarf the near-term upside. Space-based production may fail to beat terrestrial methods on cost or reliability, given launch risk, contamination, and quality-control issues.
"Patent-protected crystal forms from space may outpace terrestrial formulation gains if launch cadence improves."
Claude's terrestrial obsolescence thesis overlooks patentable crystal polymorphs unique to microgravity, as Merck's Keytruda approval already demonstrates exclusivity potential. This connects directly to Gemini's launch-bottleneck concern: if SpaceX reaches weekly cadence by 2027, per-unit costs could fall below the threshold where even improved Earth methods lose on total system economics for high-viscosity biologics. Unaddressed QC validation under variable reentry G-forces remains the sharper near-term blocker.
"Patentability of space-grown polymorphs doesn't guarantee commercial viability if reentry G-forces compromise crystal integrity or if terrestrial methods achieve equivalent bioavailability at 1/10th the cost."
Grok's patentable polymorph argument assumes regulatory exclusivity translates to commercial moat—but Merck's September approval doesn't prove BioOrbit can replicate that. More critically: weekly SpaceX cadence by 2027 is speculative. Current manifest shows ~monthly heavy-lift capacity. Even if achieved, per-unit costs must undercut terrestrial spray-drying (~$50-200/kg) to justify launch overhead. The QC reentry risk Grok flags is real, but nobody's addressed: if crystals degrade under G-force, the entire value proposition collapses before economics matter.
"The critical failure point is not just launch economics, but the chemical stability of proteins during the high-stress, high-heat reentry process."
Claude and Grok are missing the primary failure mode: the 'cold chain' of space. Even if crystals survive reentry, the transition from a microgravity-grown state to a stable, room-temperature, self-injectable formulation is a massive chemical engineering hurdle. If the drug requires refrigeration post-launch, the 'home-delivery' value proposition evaporates. BioOrbit isn't just fighting launch costs; they are fighting the thermodynamics of protein stability during the chaotic, high-heat, high-vibration return phase of space logistics.
"Polymorph-based IP is unlikely to provide a durable commercial moat for BioOrbit; rivals will find ways to bypass form-specific patents and regulatory routes won't guarantee long exclusivity."
Grok, your moat argument rests on patentable polymorphs delivering durable exclusivity. In practice, market protection for a single crystal form is fragile: patents can be narrow, regulators may demand bridging data, and clinical validation doesn’t guarantee commercial moat. Merck’s Keytruda precedent proves utility, not lasting IP protection. Competitors could pursue alternative crystallization routes or formulations, eroding any first-mover advantage even if BioOrbit hits early clinical milestones.
The panel is neutral on BioOrbit's Box-E unit, acknowledging its innovative potential but raising significant concerns about economics, regulation, and technical challenges.
Potential patentable polymorphs unique to microgravity could provide a commercial moat, but this is uncertain and depends on regulatory exclusivity and competitive responses.
The primary failure mode: the 'cold chain' of space, i.e., maintaining protein stability during the high-heat, high-vibration return phase of space logistics, which could negate the 'home-delivery' value proposition.